RxDoctor Payments Data

Jessica Augustine

Medical · Stamford, CTNPI 1366106940

Payments from drug & device makers

$493in general payments, 2019–2025

Across 10 payments — averaging $49.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$143
  • Novo Nordisk$124
  • Janssen Products, LP$85
  • Johnson & Johnson$43
  • Medtronic$27
  • Lexicon Pharmaceuticals, Inc.$26
  • plus $45 from 2 others

What the payments were for

  • Food & beverage$38177%
  • Education$11223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$493 in reported general payments places this provider in the 60th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$9,876
Medicare patients
92
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala28$138,133
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$72,609
EliquisApixaban45$42,047
DescovyEmtricitabine/Tenofov Alafenam18$39,607
XareltoRivaroxaban34$24,532
OzempicSemaglutide17$16,304
Breo ElliptaFluticasone/Vilanterol36$13,735
VascepaIcosapent Ethyl19$6,896
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,177
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,224
Albuterol Sulfate HfaAlbuterol Sulfate27$812
Atorvastatin Calcium72$644
Rosuvastatin Calcium59$535
ValacyclovirValacyclovir Hcl15$451
Metoprolol Succinate41$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$22$177,74146 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$143$91,521138 claims
Johnson & JohnsonXarelto$43$24,53234 claims
Novo NordiskOzempic$124$16,30417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 592 medical providers in Connecticut.

Other medical in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →